In 2022, one of the winners of the AgeingFit Innovation Pitches was Phlecs
Phlecs is a Dutch start-up founded by 4 former PHILIPS employees with many years of experience in photo-dermatology. Over the last 15 years extensive clinical research has been conducted on photo-dermatology treatments using UV-free LED lighting. Many studies have been published that show the efficacy of blue light therapy for the treatment of skin diseases such as Psoriasis, Eczema or itching. New studies, not yet published, confirm the safety and effectiveness of blue light therapy for the treatment of inflammatory skin diseases such as elderly itching. The Phlecs Full Body Blue Research device that has been introduced last year after obtaining the medical CE certification. The device is currently used by dermatology clinics to do research on blue light and will be used in large nursing homes that have the facility to provide the treatment. Phlecs has initiated the development of a Full Body Home connected device that brings therapy at patient’s bed with 2 patent filings this year. This device will be launched in 2026, sold to nursing homes and home care service providers.
Discover below the feedback from David Aubert, Co-Founder & Director
Phlecs is delighted to receive the Ageing Fit 2022 innovation award, for their Ful Body Blue Light device that leverages more than 15 years of clinical research and technology development originated at Philips. Elderly itching impacts significantly older adults’ quality of life and current treatments have important limitations due to overmedication, potential side effects and the time it requires to provide skin care. Ageing Fit 2022 was the perfect place for Phlecs to introduce its innovation, the Full Body Blue Light, a phototherapy device that treats elderly itching, and related comorbidities such as hypertension and depression. Ageing Fit 2022 has been very successful for us, we have made many contacts with potential customers and partners. We are grateful to receive this award because it will help us to increase the market traction and convince investors for the Series A round, we have just initiated.
